文献速递皮肤肿瘤

5%氢氧化钾溶液对比3%双氯芬酸治疗光化性角化病的随机对照试验

KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis - Results from a three-armed RCT.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-09-25

该三臂随机对照试验纳入631例轻中度光化性角化病患者,比较5%氢氧化钾溶液与3%双氯芬酸凝胶及安慰剂的疗效与安全性。结果显示氢氧化钾组治疗成功率45.2%,高于双氯芬酸组23.8%和安慰剂组22.9%,且起效更快,长期疗效与耐受性相当。

要点

  • 5%氢氧化钾溶液治疗轻中度光化性角化病疗效优于安慰剂和3%双氯芬酸凝胶。
  • 氢氧化钾起效更快,1个月时完全清除率16.0%高于双氯芬酸的9.2%。
  • 氢氧化钾与双氯芬酸长期疗效和耐受性相当,不良反应多为轻度和局部。

核心结论

  • 5%氢氧化钾溶液治疗轻中度光化性角化病优于安慰剂,且相比3%双氯芬酸凝胶在治疗结束时疗效显著更高、起效更快,长期疗效和耐受性相当。

研究设计与样本

  • 随机对照试验,共纳入631例轻中度光化性角化病患者。
  • 氢氧化钾或安慰剂双盲每日两次外用28天,停药28天为一个周期,最多三个周期或至治疗成功。
  • 第三臂双氯芬酸每日两次外用60天,研究者盲法评估。

主要发现

  • 治疗成功率:氢氧化钾组45.2%,双氯芬酸组23.8%,安慰剂组22.9%。
  • 单个病灶完全缓解率:氢氧化钾组65.0%,双氯芬酸组45.9%,安慰剂组39.9%。
  • 1个月时完全清除率:氢氧化钾组16.0%,双氯芬酸组9.2%。
  • 6个月时两种药物疗效趋同。
  • 大多数不良反应为轻度和局部,氢氧化钾与双氯芬酸耐受性相当。

临床怎么用

  • 5%氢氧化钾溶液可作为轻中度光化性角化病病灶导向治疗的有效选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Actinic Keratosis (AK) has the potential to progress into malignant cancer, thus necessitating timely and effective treatment. Despite several existing therapies, there is still a need for effective, well-tolerated therapeutic options, especially in the early treatment of patients with few isolated lesions in primary care. OBJECTIVES: To investigate the efficacy and safety of potassium hydroxide (KOH) 5% solution in comparison to diclofenac 3% gel and placebo for the treatment of mild-to-moderate AK. METHODS: In this randomized controlled trial, patients with mild or moderate AK applied KOH or placebo solution double-blinded twice daily for 28 days, followed by a 28-day off-treatment phase (1 treatment cycle) for up to three treatment cycles or until treatment success. In a third arm, diclofenac was applied twice daily for 60 days and evaluated investigator-blinded. The primary endpoint was treatment success, defined as complete clearance (CC) of all initially present AK lesions per patient at the end of treatment (EOT). RESULTS: In total, 631 patients were enrolled. Treatment success was achieved by 45.2% of patients treated with KOH, compared to 23.8% and 22.9% with diclofenac and placebo, respectively. Similarly, complete remission rates for individual lesions were higher with KOH (65.0%) than with diclofenac (45.9%) or placebo (39.9%). KOH showed a faster onset of action, with higher CC rates already after 1 month compared to diclofenac (16.0% vs. 9.2%) and converging efficacies after 6 months. Most adverse reactions were mild and localized, with comparable tolerability of KOH and diclofenac. CONCLUSIONS: KOH 5% solution proved superior to placebo and, when compared to diclofenac 3% gel, demonstrated significantly higher efficacy at EOT, as well as faster onset of action with comparable long-term efficacy and tolerability. KOH 5% solution is a valuable addition to the available treatment options for lesion-directed therapy in patients with mild-to-moderate AK. GOV IDENTIFIER: NCT04552327. Repeatedly sun‐damaged skin can develop rough, scaly patches called actinic keratosis, which may eventually develop into skin cancer. In a trial with 631 adult patients at German medical centers, researchers tested whether a potassium hydroxide (KOH) solution could treat these patches compared to an often‐used standard therapy and to an inactive control (placebo). The results show that KOH solution is effective and safe in the therapy of early‐stage disease and quickly produces noticeable results. This makes KOH a useful option when choosing treatments for patients with early signs of actinic keratosis.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Reinhold U, Leitz N, Dominicus R, et al. KOH 5% solution versus diclofenac 3% for the treatment of actinic keratosis - Results from a three-armed RCT. J Eur Acad Dermatol Venereol. 2025. PMID: 40996107. doi:10.1111/jdv.70069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。